prikaz prve stranice dokumenta Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia
  Download
PDF 732.57 KB
Scientific paper - Original scientific paper
Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia
CNS Neuroscience & Therapeutics, 24 (2018), 8; 734-740. https://doi.org/10.1111/cns.12814
Kiđemet-Piskač, Spomenka; Babić Leko, Mirjana; Blažeković, Antonela; Langer Horvat, Lea; Klepac, Nataša; Sonicki, Zdenko; Kolenc, Danijela; Hof, Patrick R.; Boban, Marina; Mimica, Ninoslav; Borovečki, Fran; Šimić, Goran

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Kiđemet Piskač, S., Babić Leko, M., Blažeković, A., Langer Horvat, L., Klepac, N., Sonicki, Z. ... Šimić, G. (2018). Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neuroscience & Therapeutics, 24. (8), 734-740. doi: 10.1111/cns.12814

Kiđemet Piskač, Spomenka, et al. "Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia." CNS Neuroscience & Therapeutics, vol. 24, no. 8, 2018, pp. 734-740. https://doi.org/10.1111/cns.12814

Kiđemet Piskač, Spomenka, Mirjana Babić Leko, Antonela Blažeković, Lea Langer Horvat, Nataša Klepac, Zdenko Sonicki, Danijela Kolenc, et al. "Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia." CNS Neuroscience & Therapeutics 24, no. 8 (2018): 734-740. https://doi.org/10.1111/cns.12814

Kiđemet Piskač, S., et al. (2018) 'Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia', CNS Neuroscience & Therapeutics, 24(8), pp. 734-740. doi: 10.1111/cns.12814

Kiđemet Piskač S, Babić Leko M, Blažeković A, Langer Horvat L, Klepac N, Sonicki Z, and sur.. Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neuroscience & Therapeutics [Internet]. 2018 August [cited 2024 November 22];24(8):734-740. doi: 10.1111/cns.12814

S. Kiđemet Piskač, et al., "Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia", CNS Neuroscience & Therapeutics, vol. 24, no. 8, pp. 734-740, August 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:920903. [Accessed: 22 November 2024]

Metadata
Title (english)Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia
AuthorSpomenka Kiđemet-Piskač
AuthorMirjana Babić Leko
AuthorAntonela Blažeković
AuthorLea Langer Horvat
AuthorNataša Klepac
AuthorZdenko Sonicki
AuthorDanijela Kolenc
AuthorPatrick R. Hof
AuthorMarina Boban
AuthorNinoslav Mimica
AuthorFran Borovečki
AuthorGoran Šimić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
BACKGROUND: The diagnosis of either Alzheimer's disease (AD) or vascular dementia (VaD) is still largely based on clinical guidelines and exclusion of other diseases that may lead to dementia. ----- AIMS: In this study, we assessed whether the use of sensitive and specific biomarkers such as phosphorylated tau proteins could contribute to an earlier and more accurate diagnosis of AD and VaD, as well as to their differentiation. ----- MATERIAL AND METHODS: A total of 198 patients, of which 152 had AD, 28 VaD, and 18 were healthy controls (HC), were included in the analyses. We analyzed cerebrospinal fluid (CSF) levels of total tau protein (t-tau), tau protein phosphorylated at threonine 231 (p-tau231), and factor score (FS) determined by combination of p-tau231 and Mini-Mental State Examination (MMSE) in patients with AD and VaD, as well as in HC. We tested the diagnostic accuracy of these biomarkers in the CSF and FS (p-tau231, MMSE) in differentiating AD from VaD and HC. ----- RESULTS: Total tau levels were significantly elevated in subjects with AD compared to HC, as well as in VaD subjects compared to HC. ----- DISCUSSION: p-tau231 levels were significantly higher in patients with ADvsHC as well in patients with VaD vsHC. p-tau231 levels did not distinguish AD from VaD patients. Importantly, FS(p-tau231 and MMSE) showed statistically significant differences in the distribution of subjects with AD and VaD. ----- CONCLUSION: These results indicate that FS (p-tau231 and MMSE) has a strong potential to provide an early distinction between AD and VaD.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCNS Neuroscience & Therapeutics
Numberingvol. 24, no. 8, pp. 734-740
p-ISSN1755-5930
DOIhttps://doi.org/10.1111/cns.12814
URN:NBNurn:nbn:hr:105:920903
Publication2018-08
Document URLhttps://doi.org/10.1111/cns.12814
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 10:22:32